Hvilken er prisen på AP Biosciences Inc (6945)

Prisen på AP Biosciences Inc (6945) er $3.06

Hva er markedsverdien på AP Biosciences Inc (6945)

Markedsverdien på AP Biosciences Inc (6945) er $296.40M

AP Biosciences Inc (6945) Fortjeneste per Aksje

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

År	EPS	Endre
Ikke nok data for de angitte datoene.

År

EPS

Endre

Ikke nok data for de angitte datoene.

Selskap	EPS	EPS-forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Selskap

EPS

EPS-forskjell

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$17.32

Argenx SE

ARGX.US

$27.74

Moderna, Inc.

MRNA.US

$-7.98

CSL Limited

CSL.AX

$-5.29

Lonza Group AG

LONN.SW

AP Biosciences Inc

6945

Kategori